UNSPSC 51101680: Quinfamide

This classification denotes an antiprotozoal agent with the molecular formula C16H13Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1ZB1046R1, chemically known as 2-furoic acid ester with 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol but generally known as quinfamide, which bears US NIH Compound Identifier 71743. European Medicines Agency schedules Quinfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10215MIG. The term QUINFAMIDE is an International Non-Proprietary Name.

UNSPSC 51101680 Quinfamide, a Commodity code, is not reflected in the recent state and local procurement activity recorded under it. The two opportunities posted under this code involve pharmaceutical procurement — one a completed piggyback award for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through the Illinois Department of Public Health, and the other a competitive bid from Seminole County, Florida for Naloxone and drug deactivation systems — neither of which aligns with the nominal scope of a specific chemical compound. The mismatch suggests either miscoding in the underlying state and local opportunity records or that the code is not in active use for commodity-level procurement activity under its stated definition.

No open solicitations under UNSPSC 51101680 are currently active. The Illinois Department of Public Health awarded a pharmaceutical piggyback contract to Chartwell Rx LLC on August 28, 2026 for antibiotic tablets valued at $2,999,999.11 over three years through the MMCAP Infuse consortium, and Seminole County released an IFB on June 30, 2026 for Naloxone and drug deactivation systems with a July 26, 2026 response deadline — but neither procurement maps meaningfully to Quinfamide or demonstrates open market activity under this Commodity code.